

CERTIFICATE OF ANALYSIS No.: 2024-15388

CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8 1000 Ljubljana, Slovenija

SAMPLE *

DR KENT GLUCOSAMINE CBD CREAM





Sample condition:	SUITABLE	Work order:	2024-111413	Sample received:	21/10/2024
Sample ID:	2443007	Analysis ID:	2024_341	Start of analysis:	21/10/2024
Sample type:	Cream	Method ID:	PHL_RPC_16C	End of analysis:	22/10/2024
Batch No.: *	KCG01124302A	Method SOP:	MET-LAB-001-08	Analyst:	Valentina Malin

^{*} Information provided by the client.

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	<loq< th=""><th>n/a</th><th></th></loq<>	n/a	
CBDA	- Cannabidiolic acid	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBGA	- Cannabigerolic acid	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBG	- Cannabigerol	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBD	- Cannabidiol	1.081	0.054	
THCV	- Tetrahydrocannabivarin	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBN	- Cannabinol	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
Δ ⁹ -THC	- Δ-9-Tetrahydrocannabinol	0.0449	0.0099	
Δ ⁸ -THC	- Δ-8-Tetrahydrocannabinol	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBL	- Cannabicyclol	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBC	- Cannabichromene	0.0304	0.0067	<u> </u>
Δ ⁹ -THCA	A - Δ-9-Tetrahydrocannabinolic acid	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBV	- Cannabivarin	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBCA	- Cannabichromenic acid	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBT	- Cannabicitran	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	
CBE	- Cannabielsoin	<loq< td=""><td>n/a</td><td></td></loq<>	n/a	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. Expanded Uncertainty was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:	Approved by:	Authorized by:
22/10/2024	Aley	Jany Pats
	mag. Janja Ahej	dr. Boštjan Jančar
	Analytical Laboratory Manager	Chief Technology Officer
End of Certificate		